I wonder if there might be considerable blowback if topline data were extremely good and at the same time the company had to confess they didn't have the technology to administer their vaccine to all but a few patients.
I am absolutely ok with JTM. New data is new data no matter which journal it comes out. We had the blinded data in the JTM and everyone is still referring that journal. Data will speak for itself. I am ok with any journal.